相关实验视频

Updated: May 5, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

在泰国微消除C型肝炎,Phetchabun模型:进展,挑战和未来方向

Yong Poovorawan^1,2, Sitthichai Kanokudom¹, Nungruthai Suntronwong¹

¹Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Journal of clinical medicine

|June 13, 2025

概括

泰国泰国泰国泰国

科学领域:

肝病学和病毒性肝炎
公共卫生和流行病学
传染病控制和控制传染病

背景情况:

肝炎C病毒 (HCV) 仍然是全球重要的健康问题,导致慢性肝病和癌症.
由于公共卫生干预,泰国的HCV患病率从20世纪90年代的约2%下降.
在特定的高风险人群中,HCV感染仍然存在,因此需要有针对性的消除策略.

研究的目的:

审查泰国C型肝炎病毒的流行病学,基因型分布和消除策略.
评估Phetchabun模型作为实现世界卫生组织C型肝炎消除目标的潜在蓝图.
在现实环境中分析分散的测试治疗策略的有效性.

主要方法:

一个叙事审查,综合来自多个来源的数据,包括科学数据库 (PubMed,Scopus),健康网站,政府报告和当地通信.
2004年,2014年和2024年进行的国家HCV流行调查的分析.
详细检查Phetchabun模型的分散的试验到治疗方法,包括查和治疗结果.

主要成果:

泰国的全国HCV流行率从2004年的2.15%下降到2024年的0.56%.
费查本模型选了88.64%的目标人群,其中4.88%的测试结果呈抗HCV阳性,72.61%的测试结果呈HCV-RNA阳性.
超过88%的感染者接受了直接作用抗病毒药物 (SOF/VEL),达到超过96%的持续病毒学反应率.

结论:

飞查本模型为消除C型肝炎提供了一个可扩展和有效的去中心化策略.
需要继续努力,以解决测试成本,提高获得护理的机会,并将微量消除策略纳入国家政策,以实现世卫组织2030年目标.
针对性的干预措施对于在泰国高风险人群中消除HCV至关重要.

关键词:

这就是Phetchabun.泰国泰国泰国泰国挑战挑战挑战挑战挑战流行病学流行病学未来的方向未来的方向基因型基因型基因型型肝炎C型肝炎的发生微清除微清除微清除微清除模型模型模型模型模型模型公共卫生公共卫生.

更多相关视频

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...